Lucror Analytics

Lucror Analytics is a leading credit and ESG research specialist and a provider of technology solutions for differentiated fixed income strategies. Our roots are in bottom-up fundamental credit analysis with a specialization in high yield corporate credits from Europe, Asia and Latin America. We are one of few research specialists integrating ESG considerations with fundamental credit research through a dedicated ESG platform. Our ESG assessment covers five key criteria: Disclosure, E,S, & G Pillars, Controversies, ESG Impact on Credit and ESG Momentum.

Recognizing the importance and value-add of Factor Investing in fixed income, Lucror developed the Smart Quant Navigator (SQN), an intuitive platform that helps clients devise and implement factor-based strategies ranging from pure quant to active fundamental, with integrated ESG.

Our company has been at the forefront of developments in the fixed income markets, identifying opportunities and consistently delivering new products and value-adding solutions to clients. Lucror has close relationships with the largest and most reputable asset managers, family offices, hedge funds, investment and wealth managers globally.

High Yield Experts

Senior Credit Analyst, Lucror Analytics

Trung Nguyen

Senior Credit Analyst

Credit

<p><br/> Glenmark Pharmaceuticals’ Q4/19-20 results were better than expected, with a turnaround in profitability. The improved performance was attributed to higher demand and increased market share after some competitors faced supply issues due to COVID-19. API suppliers tend to be in China, and many are in Wuhan, the epicentre of COVID-19. Hence, Glenmark benefited from its ability to produce most of its API in-house. The financial risk profile improved slightly, especially in terms of coverage and cash flow ratios. Liquidity is sound.<br/></p>

  Glenmark Pharmaceuticals’ Q4/19-20 results were better than expected, with a turnaround in profitability. The improved performance was attributed to higher demand and increased market share after some competitors faced supply issues due to COVID-19. API suppliers tend to be in China, and many are in Wuhan, the epicentre of COVID-19. Hence, Glenmark benefited from its ability to produce most of its API in-house. The financial risk profile improved slightly, especially in terms of coverage and cash flow ratios. Liquidity is sound. 

Glenmark Pharmaceuticals - Earnings Flash - Q4 And FY 2019-20 Results - Lucror Analytics